On October 16, 2025, Praxis Precision Medicines, Inc. reported significant positive results from their Phase 3 Essential3 study of ulixacaltamide for essential tremor, showing a 4.3 point improvement in patient scores (p<0.0001) compared to placebo. This is a significant event as they plan to submit a new drug application (NDA) by early 2026.